---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-015276"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:30:43.099702+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Omeros Q3 OMIDRIA rev $30M (+4.1% QoQ); net loss narrows; FDA CRL for narsoplimab

## Summary
- OMIDRIA revenue $30.0M in Q3, up 4.1% from Q2 $28.8M; driven by ASC growth.
- Net loss $22.7M ($0.36/sh) improved from $28.6M ($0.46/sh) in Q2; cash $50.4M.
- CMS confirmed separate payment for OMIDRIA in ASC for 2022; NOPAIN Act has 34 Senate/74 House sponsors.
- Received FDA Complete Response Letter for narsoplimab BLA in HSCT-TMA; preparing Type A meeting.
- Phase 1 data for OMS906 shows high alternative pathway suppression; moving directly into PNH patients.

## SEC filing metadata
- accession: 0001558370-21-015276
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000155837021015276/0001558370-21-015276-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000155837021015276/omer-20211109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-015276
- JSON: https://secwatch.observer/filing/0001558370-21-015276.json
- Plain text: https://secwatch.observer/filing/0001558370-21-015276.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.